Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INDACATEROL ACETATE & GLYCOPYRRONIUM BROMIDE & MOMETASONE FUROATE

All products: Limited Use (codes 627)

Other products in the same Health Canada class (R03A) — coverage varies; not interchangeable

  • Indacaterol + mometasone furoate (Atectura Breezhaler): limited Use 626

Enerzair Breezhaler · DIN 02501244 · 150mcg & 50mcg & 160mcg · Inh Pd-capsule

Limited Use — Reason for Use code 627 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 627 required
Write on scriptLU code 627 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 627
Reason for Use code 627 For the treatment of asthma in adult patients inadequately controlled with a maintenance combination of a long-acting beta-2 agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous 12 months. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Enerzair Breezhaler · DIN 02501244 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-11-05 · brand ENERZAIR BREEZHALER · ATC R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, GLYCOPYRRONIUM (GLYCOPYRROLATE) 50 MCG, MOMETASONE FUROATE 160 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Enerzair Breezhaler: Formulary list price $3.4277/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.4277 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99087 · Verify on the e-Formulary ↗ (DIN 02501244)

Source record
DIN 02501244: Enerzair Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400122; group id 713; item number 1763; lccId 00355; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 50mcg & 160mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.4277; ministry $3.4277 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02501244 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99087
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

INDACATEROL ACETATE & MOMETASONE FUROATE

· 3 products · Limited Use, codes 626 · strengths: 150mcg & 160mcg, 150mcg & 320mcg, 150mcg & 80mcg · Inh Pd-Cap

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ENERZAIR BREEZHALER (indacaterol / glycopyrronium / mometasone furoate) is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta 2 -agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months. ENERZAIR BREEZHALER is not indicated for the relief of acute bronchospasm (see General). 1.1 Pediatrics Pediatrics (<18 years of age): The safety and efficacy of ENERZAIR BREEZHALER in pediatric patients below 18 years of age have not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): No dose adjustment is required in patients 65 years of age or older (see 10.3 Pharmacokinetics). https://pdf.hres.ca/dpd_pm/00063748.PDF PM date: Jul 2, 2020 Source product: ENERZAIR BREEZHALER; DIN 02501244; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.